SCHEMBL3241906

SCHEMBL3241906

OC1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1O[C@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1O[C@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1O[C@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@@H]1O

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GJB2 P29033 3/20 0.53
PTPN1 P18031 8/20 0.48
PTPN2 P17706 3/20 0.48
PTPN11 Q06124 3/20 0.48
NT5E P21589 1/20 0.47
SLC6A2 P23975 2/20 0.46
SSTR1 P30872 1/20 0.46
SSTR2 P30874 1/20 0.46
SSTR4 P31391 1/20 0.46
SSTR3 P32745 1/20 0.46
SSTR5 P35346 1/20 0.46
GJA1 P17302 1/20 0.46
CDC25B P30305 6/20 0.45
PTPN6 P29350 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241911 1.00 GJB2 (0.53) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL5314955 0.98 GJB2 (0.55) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL1776650 0.90 PTPN1 (0.52) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL1776647 0.90 PTPN1 (0.52) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL4909410 0.89 GJB2 (0.57) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL4928707 0.89 GJB2 (0.57) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL9727044 0.89 GJB2 (0.51) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL9727043 0.89 GJB2 (0.51) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL8052999 0.88 SSTR1 (0.50) GJB2PTPN1PTPN2PTPN11NT5E
SCHEMBL8052996 0.88 SSTR1 (0.50) GJB2PTPN1PTPN2PTPN11NT5E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1232167-B1 SYNTHETIC OLIGOMANNOSIDES, PREPARATION AND USES THEREOF CT HOSPITALIER REGIONAL ET UNI (FR) 2010-05-05 EP disclosed
US-20060270627-A1 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2006-11-30 US disclosed
US-7109182-B2 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2006-09-19 US disclosed
US-20030105060-A1 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105060-A1 Synthetic oligomannosides, preparation and uses thereof DDOST, MANBA, ALG1 GJB2 4055/4885PTPN1 1241/4885PTPN2 1234/4885
US-20060270627-A1 Synthetic oligomannosides, preparation and uses thereof DDOST, MANBA, ALG1 GJB2 4055/4885PTPN1 1241/4885PTPN2 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.